Company on the label
Genentech, Inc.
37 prescription drugs on current FDA listings. Its labels name 10 plants.
Plants named on its labels
| Plant | Where | Role | Last FDA inspection |
|---|---|---|---|
| F. Hoffmann-La Roche AG | Kaiseraugst, Switzerland | Makes it, makes the active ingredient, tests it, packages it and labels it | Problems found, fixed voluntarilyMar 2025 |
| Genentech, Inc. | Oceanside, CA, United States | Makes the active ingredient and tests it | No problems foundAug 2024 |
| Roche Diagnostics GmbH | Penzberg, Germany | Makes the active ingredient and tests it | Problems found, fixed voluntarilyMay 2025 |
| F. Hoffmann-La Roche AG | Basel, Switzerland | Makes it, makes the active ingredient and tests it | Problems found, fixed voluntarilyMay 2025 |
| Roche Diagnostics GmbH | Mannheim, Germany | Makes it, tests it, packages it and labels it | Problems found, fixed voluntarilyOct 2021 |
| Genentech, Inc. | South San Francisco, CA, United States | Makes it, makes the active ingredient, tests it, packages it and labels it | No problems foundMay 2026 |
| Genentech, Inc. | Hillsboro, OR, United States | Makes it, tests it, packages it and labels it | Problems found, fixed voluntarilyApr 2024 |
| Roche Singapore Technical Operations Pte. Ltd. | Singapore, Singapore | Makes the active ingredient and tests it | Problems found, fixed voluntarilyNov 2025 |
| Sharp Packaging Services, LLC | Conshohocken, PA, United States | Packages it | No problems foundFeb 2026 |
| Lonza Biologics Tuas Pte. Ltd. | Singapore, Singapore | Tests it | Problems found, fixed voluntarilyJun 2023 |
Drugs
- Alectinib 50242-130
- Alteplase 50242-085, 50242-041, 50242-044
- Atezolizumab 50242-917, 50242-918
- Atezolizumab and Hyaluronidase (human Recombinant) 50242-933
- Baloxavir 50242-599, 50242-860, 50242-617 +2
- Bevacizumab 50242-060, 50242-061
- Cobimetinib 50242-717
- Crovalimab 50242-115
- Dornase Alfa 50242-100
- Emicizumab 50242-922, 50242-927, 50242-923 +3
- Entrectinib 50242-091, 50242-094, 50242-623
- Faricimab 50242-096
- Glofitamab 50242-127, 50242-125
- Hyaluronidase (human Recombinant) and Ocrelizumab 50242-554
- Hyaluronidase (human Recombinant) and Pertuzumab and Trastuzumab 50242-260, 50242-245
- Hyaluronidase (human Recombinant) and Rituximab 50242-108, 50242-109
- Hyaluronidase (human Recombinant) and Trastuzumab 50242-077
- Inavolisib 50242-084, 50242-079
- Mosunetuzumab 50242-159, 50242-142, 50242-201 +1
- Mycophenolic Acid 0004-0261, 0004-0259, 0004-0260 +1
- Obinutuzumab 50242-070
- Ocrelizumab 50242-150
- Omalizumab 50242-215, 50242-040, 50242-227 +1
- Oseltamivir Acid 0004-0802, 0004-0801, 0004-0822 +1
- Pertuzumab 50242-145
- Pirfenidone 50242-121, 50242-122, 50242-123
- Polatuzumab Vedotin 50242-105, 50242-103
- Ranibizumab 50242-080, 50242-078, 50242-082
- Risdiplam 50242-175, 50242-202
- Rituximab 50242-051, 50242-053
- Satralizumab 50242-007, 50242-005
- Tenecteplase 50242-014, 50242-120, 50242-176
- Tocilizumab 50242-138, 50242-143, 50242-136 +2
- Trastuzumab 50242-132
- Trastuzumab Emtansine 50242-088, 50242-087
- Vemurafenib 50242-090
- Vismodegib 50242-140